Low-Dose Cytarabine in Myelodysplastic Syndromes and Acute Leukemia
نویسندگان
چکیده
منابع مشابه
Combined low-dose cytarabine, melphalan and mitoxantrone for older patients with acute myeloid leukemia or high-risk myelodysplastic syndrome.
BACKGROUND Low-dose cytarabine (ara-C) has been used to treat older patients with acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS), but has resulted in complete remission for <20% of cases. A pilot study of the efficacy of a combination chemotherapy using low-dose ara-C, melphalan (Mel), and mitoxantrone (Mit) was conducted. PATIENTS AND METHODS The treatment comprised...
متن کاملLow-dose cytarabine plus aclarubicin for patients with previously untreated acute myeloid leukemia or high-risk myelodysplastic syndrome ineligible for standard-dose cytarabine plus anthracycline.
BACKGROUND In order to assess the role of the combination of low-dose cytarabine (Ara-C) plus aclarubicin (CA) in remission induction for patients with untreated acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS), we retrospectively analyzed the efficacy and safety of CA. PATIENTS AND METHODS Data of twenty patients with untreated AML or high-risk MDS who were ineligible...
متن کاملA phase I study of idarubicin dose escalation with amisfostine and high-dose cytarabine in patients with relapsed acute myelogenous leukemia and myelodysplastic syndromes.
BACKGROUND AND OBJECTIVES Early studies have suggested that increasing doses of anthracycline improve outcome in younger patients with acute myelogenous leukemia (AML), but dose escalation has been precluded by the acute and chronic toxicities of these agents. Amifostine is a cytoprotective compound that has been shown to protect against the acute cytotoxicities of anthracyclines in animal mode...
متن کاملTP53 and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes.
BACKGROUND The molecular determinants of clinical responses to decitabine therapy in patients with acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS) are unclear. METHODS We enrolled 84 adult patients with AML or MDS in a single-institution trial of decitabine to identify somatic mutations and their relationships to clinical responses. Decitabine was administered at a dose of 20 ...
متن کاملDNA Repair in Acute Myeloid Leukemia and Myelodysplastic Syndromes
Acute myeloid leukemia (AML) comprises approximately 25% of all leukemias in adults in the western world. It is a clonal disorder caused by uncontrolled proliferation and accumulation of myeloid progenitor cells in the bone marrow with impaired differentiation, leading ultimately to hematopoietic failure. Myelodysplastic syndrome (MDS) is characterized by persistent pancytopenia, dysplastic hem...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Acta Haematologica
سال: 1986
ISSN: 0001-5792,1421-9662
DOI: 10.1159/000206103